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 6 
Abstract 7 
Levan, a bacterial exopolysaccharide, has been suggested to have several biological activities, 8 
such as anti-tumour activity and lowering blood pressure. There is also interest in its potential 9 
prebiotic activity. This study investigated the fermentation profile of a levan fraction from 10 
Erwinia sp. 10119 (average DP =137) throughout a three-stage continuous gut model system, 11 
in which inulin HP (average DP = 40) was included as a comparison. Levan-type fructan was 12 
found to selectively stimulate the growth of Bifidobacterium and Eubacterium rectale - 13 
Clostridium coccoides group in all fermenter vessels, with significant (p<0.05) increases in 14 
the concentration of both acetate and butyrate. The increases in Bifidobacterium population 15 
were significantly (p<0.05) higher in the models treated with levan-type fructan (0.8 to1.24 16 
log cell/mL) compared to the models treated with inulin HP (0.62-0.7 log cell/mL), indicating 17 
                                                          
Abbreviations: EPS, exopolysaccharide; DP, degree of polymerisation; inulin HP, high performance 
inulin; Mn, number average molecular weight; Mw, weight average molecular weight; PDI, polydispersity 
index; SCFA, short chain fatty acid; FOS, fructooligosaccharide; SOD, superoxide dismutase; CAT, 
catalase; FISH, fluorescent in situ hybridization; OD, optical density; NMR, nuclear magnetic resonance; 
BCA, bicinchoninic acid; BSA, bovine serum albumin; SS1, steady state 1; SS2, steady state 2; DAPI , 6-
diamidino-2-phenylindole dihydrochloride; TSP, 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt; 
MW, molecular weight. 
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a stronger bifidogenic effect of levan-type fructan and a prolonged persistence in the colon 18 
due to its higher DP. 19 
Key words: exopolysaccharide (EPS), short chain fatty acid (SCFA), gut model, gut 20 
microbiota. 21 
 22 
1. Introduction 23 
A dietary prebiotic is “a selectively fermented ingredient that results in specific changes, in 24 
the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) 25 
upon host health” (Gibson et al 2010). Various potential beneficial effects of prebiotics have 26 
been studied including, control of intestinal transit time and bowel habit, and reduction of risk 27 
of atherosclerosis, osteoporosis, obesity, type-2 diabetes, cancer, infections and allergies 28 
(Laparra and Sanz, 2010). The establishment of a prebiotic effect requires appropriate 29 
nutritional feeding trials with defined health outcomes (Gibson et al., 2010). Short chain fatty 30 
acids (SCFAs), the principle end products of microbial metabolism, can activate G-coupled-31 
receptors, inhibit histone deacetylases, and serve as energy sources, hence affect various 32 
physiological processes and may contribute to health and disease (Koh et al., 2016). Human 33 
studies, however, are not suitable for evaluating the impact on the metabolism of the 34 
microbiota as SCFAs are largely absorbed from the colon (Verbeke et al., 2015). To obtain 35 
data on faecal metabolism, in vitro gut models can be appropriate model systems.  36 
 37 
Many common diseases associated with the human large intestine, such as colon cancer and 38 
ulcerative colitis, arise in the distal colon where proteolytic fermentation predominates and 39 
potentially toxic metabolites e.g. ammonia, hydrogen sulphide, and cresol are produced 40 
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(Andriamihaja, et al., 2015; De Preter et al., 2007; Hughes, et al., 2008; Gibson, 2004; 41 
McBurney et al., 1987; Ijssennagger, et al., 2016; Oliphant & Allen-Vercoe, 2019). 42 
Consequently, there is interest in designing novel prebiotics targeting the distal region of the 43 
colon in order to reduce the products of protein metabolism and to increase saccharolytic 44 
activity which results in short chain fatty acids. As suggested by a number of studies 45 
comparing the fermentation of FOS and inulin in continuous in vitro model systems 46 
(Rumessen et al., 1990; Van de Wiele et al., 2007) and in vivo animal or human trials 47 
(Costabile et al., 2010; Patterson et al., 2010; Tuohy et al., 2001), FOS (low DP) are rapidly 48 
fermented in the proximal colon, while inulin (high DP) appears to have a more sustainable 49 
fermentation through the gut and hence may provide more functional effects in the distal 50 
colon. It is clear that there is a positive relationship between DP and the persistence of 51 
prebiotics in the gut. 52 
 53 
Inulin and levan are two main types of fructans. Inulin-type fructan consists of linear (2-1) 54 
linked β-D-fructosyl units attached to the fructosyl moiety of sucrose, with DP ranging from 55 
2 to 60. Inulin has been widely used as a prebiotic, fat replacer, sugar replacer, and texture 56 
modifier due to its versatile physicochemical properties and beneficial role in gastric health 57 
(Shoaib et al., 2016). Industrial production of inulin has been achieved by extraction from 58 
inulin containing plants, such as Jerusalem artichoke and chicory, whereas inulin from 59 
microbial sources are less well studied (Ahmed and Rashid, 2017). Levan-type fructan is 60 
linked by β (2-6) linkages with occasional β (2-1) branching. Compared with inulin, only a 61 
small amount of levan is synthesised in plants by the action of sucrose:sucrose 6 62 
fructosyltransferases (6-SST) and some other fructosyltransferases with relatively small 63 
chains (DP <10 to 100) (Öner et al., 2016). Bacterial levans on the contrary, are produced 64 
from sucrose by transfructosylation with levansucrase, and many are in the range of DP 5000 65 
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to 50000 depending on the bacteria and culture conditions (Ortiz-Soto et al., 2019).  Levan 66 
has been marketed in both Korea and Japan, with several claimed health benefits, for 67 
example, inhibiting hyperglycaemia and oxidative stress induced by diabetes (Dahech et al., 68 
2011), exhibiting anti-tumour activity against typical tumour cell lines (Abdel-Fattah et al., 69 
2012; Calazans et al., 2000; Esawy et al., 2013; Yoon et al., 2004) and increasing superoxide 70 
dismutase (SOD) and catalase (CAT) in the heart (Abdel-Fattah et al., 2012; Dahech et al., 71 
2013). However, these health claims need to be substantiated by more reliable in vivo studies. 72 
In addition to these potential activities, bacterial strains of several genera were shown to grow 73 
on levan or levan-derived FOS, i.e. Bacteroides (Adamberg et al., 2014; Sonnenburg et al., 74 
2010), Lactobacillus (Martel et al., 2010; Yong et al., 2007), Bifidobacterium (Porras-75 
Dominguez et al., 2014). Several levan degrading enzymes have also been identified in gut 76 
microbes. A fructofuranosidase from Bifidobacterium longum subsp. Infantis was found 77 
acting on structurally diverse fructans (Ávila-Fernández et al., 2016). An endo-levanase 78 
(BT1760) from Bacteroides thetaiotaomicron, an abundant commensal gut bacterium, has 79 
been biochemically studied (Mardo et al., 2017; Sonnenburg et al., 2010).  More recently, the 80 
crystal structure of BT1760 was presented by Ernits et al. (2019). The prebiotic potential of 81 
levan-type fructans has been studied by some researchers mainly using in vitro model 82 
systems or animals (Adamberg et al., 2018; Bello et al., 2001; Hamdy et al., 2018; Kang et 83 
al., 2000; Marx et al., 2000). However, results have not been consistent due to the use of 84 
different model systems and the various origins of levan-type fructans used in these studies. 85 
Adamberg et al (2018) documented that the growth of Collinsella (Actinobacteria) was 86 
enhanced at cultivation of faecal inocula on levans. However, utilisation of levans by bacteria 87 
belong to this genus can be hardly evaluated as the majority of this genus are currently 88 
uncultured (Almedida et al., 2019). On the other hand, there could be a numerous population 89 
of uncultivated gut bacteria that may respond to presence of levan-type fructan. Therefore, 90 
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the shifts in gut microbe composition brought by supplementation of levan-type fructans 91 
remain to be fully revealed. 92 
 93 
In order to evaluate the fermentation profile and gut persistence of long-chain levan-type 94 
fructan, this study was carried out using a pH controlled, three-stage continuous gut model 95 
mimicking the different regions of the human large intestine. The effects on growth and 96 
activity of gut microbiota were analysed by fluorescent in situ hybridization (FISH) and high 97 
performance liquid chromatography (HPLC).  98 
 99 
2. Materials and Methods 100 
2.1 Fermentation, fractionation and purification of levan  101 
2.1.1 Fermentation 102 
Media suitable for levan production were prepared by adding 23 % w/v sucrose into 100 mL 103 
Nutrient Broth No.2 (Oxoid) in baffled flasks (Sigma), followed by autoclaving at 121°C for 104 
15 min. Erwinia sp.10119, isolated from cherry tree gum, was purchased from the National 105 
Collections of Industrial, Marine and Food Bacteria (NCIMB). A single colony of Erwinia 106 
sp. 10119 from a 48 h pre-inoculated agar plate was incubated in 30 mL Sterilin bottles 107 
containing 10 mL Nutrient Broth overnight. This pre-incubated cell suspension was then 108 
added into 100 mL levan producing media to achieve a starting optical density (OD at 600 109 
nm) of 0.05. Flasks containing the inoculated media were incubated at 25°C on a shaking 110 




After fermentation, the culture solution was diluted 1:3 with deionised water and centrifuged 113 
at low speed (2,991 g) to spin down most of the bacterial cells. After that, a probe sonicator 114 
(Soniprep 150, MSE) was used to apply ultrasound to the supernatant at 1-micron amplitude 115 
for up to 15 min to de-aggregate the mixture. This crude liquor was then centrifuged again to 116 
completely remove residual bacteria cells. The supernatant was collected and stored in 1L 117 
Duran bottles at 4°C for no more than 24 h before next treatment.  118 
 119 
2.1.2 Levan fractionation by acid thermal hydrolysis 120 
In order to obtain lower DP Erwinia levan as the final product, the crude levan-containing 121 
supernatant was subjected to acid-thermal hydrolysis. Prior to hydrolysis, the supernatant was 122 
rapidly heated to 70°C by a steamer to minimise uneven heating throughout the container. 123 
Acid-thermal hydrolysis was carried out in an oven at 70°C without agitation; 0.1% v/v acetic 124 
acid was added into a 1 L Duran bottle containing 900 mL of the crude levan solution for 50 125 
min before being stopped by addition of 2M NaOH. The crude hydrolysis liquor was cooled 126 
to room temperature and stored at 4°C for no more than 2 days before it was passed through a 127 
membrane filtration process. 128 
 129 
2.1.3 Levan purification by membrane filtration 130 
Ultrafiltration was carried out using a high pressure test unit (Osmonic Desal, Le Mee sur 131 
Saine, France). The unit consisted of a feed tank of 4 L capacity, a piston pump and two 132 
stainless steel flow cells with a stainless porous sheet membrane support. These cross flow 133 
cells were connected in parallel. Two flat sheet asymmetric thin film composite membranes 134 
(GE, Osmonic Desal, Gilson Scientific, Luton, UK) with MWCO of 10 kDa were used.  135 
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Membranes were cut into circular forms with an area of 81cm2. Each new membrane was 136 
immersed overnight in 2 L of deionised water to remove any preservatives prior to use. 137 
Non-continuous diafiltration by volume reduction was employed, whereby the working feed 138 
volume of 3.0 L was concentrated to 1.5 L by removing the permeate, while recycling the 139 
retentate to the feet tank at 300 psi pressure. The feed was diluted back to its initial volume 140 
with deionised water and the diafiltration was repeated three times to remove more of the low 141 
molecular weight material. The purified liquor was then concentrated to 500 mL as further 142 
concentration results in insufficient circulation. The cumulative retentate was then 143 
precipitated with 3 volumes of ethanol in 250 mL Sterilin bottles and left to precipitate at 4°C 144 
overnight. After removal of ethanol, the precipitates were dried in a biosafety cabinet, 145 
reconstituted with deionised water, then store at – 80°C for 24 h and freeze dried at -55°C for 146 
48 h with a VirTis Bench Top freeze dryer (VirTis Sentry 2.0, SP Scientific, Ipswich, UK), 147 
and stored in an airtight container at room temperature for further analysis.  148 
 149 
2.2 Analysis of levan  150 
NMR was used to confirm the structure of levan by comparing the 1H NMR and 13C NMR 151 
spectra with that of levan purchased from Sigma (extracted from Erwinia herbicola). NMR 152 
samples were prepared by dissolving freeze dried levan in D2O (20 mg/mL m/v) and then 153 
analysed by Bruker Nanobay 400MHz NMR spectroscopy. One-dimensional 1H NMR 154 
spectra were obtained by applying a zg30 pulse sequence at 400MHz with a 3.9584 sec 155 
acquisition time, 1 sec relaxation delay, 8278 Hz spectral width, and 296.2 K temperature. 156 
Internal solvent D2O was used as chemical shift reference (δ = 4.79). One-dimensional 
13C 157 
NMR spectra were obtained by applying a zgpg30 pulse sequence with a 1.3665 sec 158 
acquisition time, 1.5 sec relaxation delay, 23980 Hz spectral width, and 295.2 K temperature. 159 
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3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP) was used as chemical shift 160 
reference (δ = 0.00). Analysis of the protein content in the final levan product was carried out 161 
by BCA (bicinchoninic acid) protein assay kit (Sigma). Bovine serum albumin (BSA) 162 
solutions (50-500 μg/mL) were used as standards. The working reagent was prepared by 163 
mixing 100 mL of reagent A (a solution containing bicinchoninic acid, sodium carbonate, 164 
sodium tartrate and sodium bicarbonate in 0.1N NaOH, pH 11.25) with 2mL of Reagent B 165 
(4% (w/v) CuSO4·5H2O). 2 mL of the working reagent were added to each Eppendorf 166 
containing 0.1 mL of BSA standards or freeze dried levan sample (10g/L). After that, these 167 
mixed solutions were incubated at 37 ºC for 30 mins. After incubation, the absorbance was 168 
read at 562 nm. The apparent molar mass was determined by HPLC-RI (Agilent 1100 series, 169 
Winnersh, UK) using a PL aquagel-OH MIXED-H 8μm size exclusion column (Varian, 170 
INC., England) before and after hydrolysis. The column temperature was 30 ̊C and HPLC 171 
grade water was used as mobile phase at 0.4 mL/min. Sucrose，glucose，FOS，inulin ST 172 
and Dextrans (50-1400kDa) were used as external standards. Size exclusion chromatography 173 
was also used to determine retention of desired levan fraction after ultrafiltration. 174 
 175 
2.3 Three-stage continuous culture system  176 
A scaled-down version of the three-stage continuous culture simulation of the human colon 177 
(Macfarlane et al., 1998) was used to investigate the effect of a hydrolysed levan fraction 178 
from Erwinia sp. 10119, on the faecal microbiota. The scaled down system was run at the 179 
same dilution rate (i.e., a rate at which fresh medium was added) to the conventional gut 180 
model when operating at a retention time of 48 h (flow rate of 6.25ml/h). The gut model 181 
system includes three glass fermenters simulating conditions in the proximal colon (Vessel 1, 182 
80 mL, pH 5.5), transverse (Vessel 2, 100 mL, pH 6.2) and distal colon (Vessel 3, 120 mL 183 
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pH 6.8) and was fed with a complex medium through a peristaltic pump (Watson-Marlow, 184 
Cornwall, UK). The intervention dose used in this study (3 g/day) was selected based on 185 
previous human studies (Costabile et al., 2010; Tuohy et al., 2001), 8 g/day and 10 g/day 186 
respectively. An average of 9g/day (provides 18 kcal of energy per day) was selected, 187 
however, as a scaled-down model was used, containing one-third of the normal medium 188 
volume, a value of 3g/day was added to the system (Macfarlane et al., 1998). The entire 189 
system, including the medium reservoir, was constantly stirred and maintained in an 190 
anaerobic condition by continuously sparging with nitrogen. The pH of each vessel was 191 
automatically adjusted using pH controllers (Fermac 260; Electrolab, Tewkesbury, UK) by 192 
adding 0.5 N HCL and 0.5 N NaOH. The temperature of the culture was maintained at 37 °C 193 
by a circulating water bath. Sterile vessels were filled with pre-sterilized medium containing 194 
(per litre): 5 g starch, 5 g peptone water, 5 g tryptone, 4.5 g yeast extract, 4.5 g NaCl, 4.5 195 
KCl, 4 g mucin, 3 g casein, 2 g xylan, 2 g arabinogalactan, 1.5 g NaHCO3, 1.25 g 196 
MgSO4·7H2O, 1 g guar gum, 1 g inulin (Orafti
® ST, Beneo, Tienen, Belgium), 0.8 g cysteine-197 
HCl, 0.5 g KH2PO4, 0.5 g K2HPO4, 0.4 g bile salts, 0.15 g CaCl2·6H2O, 0.005 g FeSO4, 0.05 198 
g haemin, 1 mL Tween 80, 0.01 mL vitamin K and 4 mL resazurin solution (0.25 g/L)  as a 199 
redox indicator.  200 
 201 
Vessels were inoculated with freshly prepared faecal slurries (20% w/w in PBS). The faecal 202 
slurries were prepared in strainer stomacher bags (Seward, UK) to remove large particles and 203 
were homogenised in a stomacher (Stomacher 400; Seward, West Sussex, UK) for 2 min at 204 
medium speed. Faecal samples from three healthy adults were used, each of them was used to 205 
inoculate two gut models (one for levan and one for inulin HP). Volunteer selection was 206 
based on three criteria, i.e., generally healthy without any current medication; should not 207 
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have taken any antibiotics or pro/pre-biotic tablets over the last 6 months, should not be a 208 
frequent consumer of pro/prebiotic containing food or beverages. 209 
 210 
For each donor, two gut models were inoculated in parallel, 28.6 mL (V1), 33.3 mL (V2), and 211 
37.5 mL (V3) were inoculated into culture medium (51.4 mL (V1), 66.7 mL (V2), 82.5 mL 212 
(V3)). The systems were run as batch cultures for the first 24 h after inoculation to stabilise 213 
the bacterial populations. After this, all the vessels were connected and the medium flow was 214 
initiated until eight full volume turnovers (16 days) were completed (steady state 1, SS1). 5 215 
mL of sample were taken from each vessel on 3 consecutive days for analysis of bacterial 216 
populations and SCFA accumulation. Once stable organic acid profiles were obtained, 3 g of 217 
hydrolysed levan or inulin HP (Orafti® HP, Beneo, Tienen, Belgium) were added into vessel 218 
1 of the respective gut models on a daily basis for another eight turnovers (16 days), until 219 
stable organic acid profiles were observed from samples taken on 3 consecutive days (steady 220 
state 2, SS2).  221 
 222 
2.4 Bacterial enumeration  223 
Bacterial groups were enumerated using fluorescent in situ hybridization (FISH) with 16S 224 
rRNA oligonucleotide probes (Table 1). The probes were labelled with the fluorescent Cy3 225 
dye as described by Sarbini et al. (2011). Samples (375 mL) were fixed for 4 h at 4° C with 226 
4% (w/v) filtered paraformaldehyde (pH 7.2) in a ratio of 1:4 (v/v), washed twice with 227 
filtered PBS (0.22 μm pore size), and resuspended in 300 mL of a PBS–ethanol mixture (1:1, 228 
v/v). Prior to hybridization, samples were diluted to appropriate concentration and 20 µl of 229 
each sample were pipetted onto Teflon- and poly-L-lysine-coated, six-well (10 mm diameter 230 
each) slides (Tekdon Inc., Myakka City, FL, USA). In order to make the cells permeable to 231 
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the hybridization buffer, the slides were dried in a bench top oven at 50°C for 15 min before 232 
being finally dehydrated in an ethanol series (50 %, 80 % and 96 % (v/v) ethanol, 3 min 233 
each). Fifty microliters of hybridization buffer (containing 5 ng probe /mL) were applied onto 234 
the surface of each well. Hybridizations were performed for 4 h in an ISO20 oven (Grant 235 
Boekel, Cambridge, UK). Hybridization temperatures for each probe are listed in Table 1. 236 
For the washing step, slides were placed in 50 mL of pre-warmed wash buffer containing 20 237 
µl of 4, 6-diamidino-2-phenylindole dihydrochloride (DAPI; 50 ng/mL; Sigma, St Louis, 238 
MO, USA) for 15 min. They were then washed (2–3 s) in ice-cold water and dried under a 239 
stream of compressed air. After that, 5 µl of antifade reagent (polyvinyl alcohol mounting 240 
medium with DABCOe antifade, Sigma) were added to each well and a coverslip was 241 
applied. Slides were stored in the dark at 4º C until cells were counted under a Nikon E400 242 
Eclipse microscope (Nikon, Kingston upon Thames Surrey, UK). Slides were counted within 243 
a week, but could be kept for up to three months due to the use of antifading agents. DAPI 244 
slides were visualised with the aid of a DM 400 filter and probe slides with the aid of a DM 245 
575 filter. Fifteen fields of view were geometrically picked and counted. The average counts 246 
were calculated and used for statistical analysis. 247 
 248 
2.5 Short chain fatty acid (SCFA) analysis  249 
A sample (1 mL) from the gut model vessels was dispensed into 1.5 mL Eppendorf tubes and 250 
centrifuged at 13 000 x g for 10 min to sediment bacteria and other solids. Supernatants were 251 
filtered using 0.2 μm polycarbonate syringe filters (Whatman International Ltd, Maidstone, 252 
Kent, UK) and injected with internal standard (diethylbutyric acid, Sigma) at a ratio of 4:1 253 
into an HPLC system (Merck, Whitehouse Station, NJ, USA) equipped with refractive index 254 
(RI) detection. The column used was an ion-exclusion REZEX ROA organic acid column 255 
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(Phenomenex, Inc., Macclesfield, Cheshire, UK) maintained at 85°C. Sulfuric acid in HPLC-256 
grade water (0.0025M) was used as the eluent and the flow rate was maintained at 0.5 257 
mL/min. The carboxylic acids in the samples were quantified using calibration curves of 258 
acetic, propionic, butyric, valeric and formic acid, in concentrations ranging between 2.5 and 259 
100 mM. 260 
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Table 1 Oligonucleotide probes and hybridisation conditions used in this study 




Formamide (%) in 
hybridization buffer 
Temperature (°C) Reference 
     Hybridization Washing  
Ato291 GGTCGGTCTCTCAACCC Atopobium group None 0 50 50 Harmsen et al. (2000) 
Bac303 CCAATGTGGGGGACCTT Bacteroides/ Prevotella None 0 46 48 Manz et al. (1996) 
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. None 0 50 50 Langendijk et al. (1995) 
Chis150 TTATGCGGTATTAATCTYCCTTT Clostridium histolyticum 
group 
None 0 50 50 Franks et al. (1998) 
Prop853 ATTGCGTTAACTCCGGCAC Clostrium cluster IX None 0 50 50 Walker et al. (2005) 
Erec482 GCTTCTTAGTCARGTACCG Eubacterium rectale- 
Clostridium coccoides 
group 
None 0 50 50 Franks et al. (1998) 
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus-
Enterococcus spp. 
Lysozyme 0 50 50 Harmsen et al. (1999) 
Rrec584 TCAGACTTGCCGYACCGC Roseburia spp. None 0 50 50 Walker et al. (2005) 
Frpau655 CGCCTACCTCTGCACTAC Faecalibacterium 
prausnitzii group 
None 0 58 58 Hold et al. (2003) 
EUB338‡ GCTGCCTCCCGTAGGAGT Total bacteria 
(mixed EUB338 probes) 
None 35 46 48 Daims et al. (1999) 
EUB338II‡ GCAGCCACCCGTAGGTGT None 35 46 48 Daims et al. (1999) 
EUB338III‡ GCTGCCACCCGTAGGTGT None 35 46 48 Daims et al. (1999) 
261 
2.6 Statistical analysis  262 
Statistical analysis was performed using SPSS for Windows, Version 18.0. A paired 263 
independent t-test was used to determine significant changes for each bacterial group and 264 
SCFA concentration between steady state 1 (SS1) of faecal fermentation without adding test 265 
substrate and steady state 2 (SS2) after adding the test substrate. One-way analysis of 266 
variance (ANOVA) and Tukey’s posthoc test were used to determine significant differences 267 
in bacterial group populations and SCFA concentrations among the different volunteers. 268 
Differences were considered to be significant when p<0.05. 269 
 270 
3. Results and Discussion 271 
3.1 Levan characterization  272 
Comparison of the chemical shifts in 13C NMR and 1H NMR spectrum of levan produced in 273 
this experiment with that for Sigma levan reveals the [→6)-β-D-Fruƒ-(2→]n main chain 274 
structure of produced levan. Chemical shifts were shown in Table 2. Residual protein was 275 
non-detectable in the final product. The result of size exclusion chromatography showed that 276 
the molecular mass of natural levan produced by Erwinia sp. 10119 was about DP 7719 (1.3 277 
x 106 Daltons), which is comparable to the previous reported molecular range weight of levan 278 
produced from Erwinia herbicola (1.1 x 106-1.6 x l06 Daltons) (Keith et al., 1991). After acid-279 
thermal hydrolysis, the molecular mass of resulting levan fraction was examined again by 280 
size exclusion chromatography. The molecular weight distribution of obtained levan fraction 281 
was illustrated in Fig.1. The hydrolysed levan fraction had a weight average molecular 282 
weight (Mw) of approximately 22220 g mol-1 (DP = 137) and a dispersity of 5.75. Membrane 283 
processing resulted in a moderate DP levan fraction with 15 % (w/w) of mono- and oligo-284 
saccharides. The results are expressed as mass percentages of the compounds left after 285 
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ultrafiltration based on GPC area measurements. Overall, the type of linkage, DP and purity 286 
of levan fractions produced by the present used method, consisting of centrifugation, 287 
sonication, acid-thermal hydrolysis and ethanol precipitation were found satisfactory, and 288 
these factions could be subjected to the three-stage gut model for further evaluation of their 289 
prebiotic potential and gut persistency.  290 
Table 2 Comparison of 1H and 13C NMR data of lavean produced in this study with Sigma 291 
Levan (Erwinia herbicola) and chemical shifts data published for levan from Bacillus sp. 3B6 292 
and Zymomonas mobilis (Angeli et al., 2009, Matulová et al., 2011)  293 
Compound         1H and/or 13C chemical shifts /δ     
        1, 1' 2 3 4 5 6, 6' 
Levan (Erwinia sp. 10119)   H 3.644 3.570 - 4.066 3.982 3.836 3.775 3.437 
   C 59.79 103.79 76.19 75.11 80.24 63.33 
          
Levan (Sigma-Erwinia herbicola) H 3.645 3.571 - 4.067 3.984 3.838 3.775 3.440 
   C 59.81 103.78 76.21 75.13 80.24 63.33 
          
Levan  
(Bacillus sp. 3B6) 
 H 3.77   3.670 - 4.178 4.096 3.958 3.898 3.549 
   C 60.75 105 77.15 76 81.07 64.2 
          
Levan (Zymomonas mobilis) H 3.8        3.7 - 4.3 4.2 4.0  3.85     3.55 






Fig.1. Molecular weight distribution of hydrolysed levan analysed by Size exclusion 297 
chromatography (n=3). Mn, number average molecular weight; Mw, weight average molecular weight; 298 
Dispersity= Mw/Mn. 299 
 300 
3.2 Changes in microbiota composition upon inulin and levan supplementation  301 
The work presented here is the first to evaluate the fermentation selectivity of levan-type 302 
fructan in a continuous gut model system. Fig. 2 shows the bacterial concentrations before 303 
(SS1) and after (SS2) the addition of test substrates. The mean values for each probe are 304 
averages of three volunteers for each substrate (inulin HP and levan-type fructan) in each 305 
vessel (V1, V2 and V3) representing different regions of the colon, i.e. proximal, transverse 306 
and distal colon. Significant stimulation (p<0.05) of Bifidobacterium was observed for both 307 
test substrates in all vessels, which is in line with results from Tuohy et al. (2001), who 308 
reported a stimulation of Bifidobacterium after an in vivo inulin HP intervention (8g/ day). In 309 
comparison, using a five-stage in vitro continuous Simulator of the Human Intestinal 310 
Microbial Ecosystem (SHIME), Van de Wiele et al. (2004) only observed an increase of 311 

























was used as a supplement at a dose equal to 5 g/day. Furthermore, the population of 313 
Bifidobacterium was significantly higher in all three vessels in the models treated with levan 314 
than with inulin HP, exhibiting a stronger bifidogenic effect of levan. This is supported by 315 
Ávila-Fernández et al. (2016), who fund that a β-fructofuranosidase from Bifidobacterium 316 
longum subsp. infantis ATCC 15697 has higher affinity for levan-type than inulin-type FOS. 317 
No significant changes were observed in population of Lactobacillus-Enterococcus for both 318 
substrates. This is in line with the results of Tuohy et al. (2002) and Harmsen et al. (2002), in 319 
which this groups of bacteria were unaffected by supplementation with inulin HP. 320 
 321 
 A decrease in Bacteroides - Prevotella (ranging from 0.1 to 0.86 log cells/mL) was observed 322 
when inulin HP was added, while there were no significant changes in the levan models. 323 
Harmsen et al., (2002) has reported similar results in a human study on inulin in which 10 324 
healthy volunteers were given inulin HP for 14 days at a dose of 9 g/day. Inulin HP did not 325 
have any significant stimulation effect on the Bacteroides – Prevotella group, and a decrease 326 
of 0.6 log cells/mL has been observed during the treatment. The decrease in number of 327 
Bacteroides was also reported by two other studies evaluating the prebiotic potential of high 328 
molecular weight inulin by human studies (Costabile et al. 2010; Tuohy et al. 2002). 329 
Moreover, Sonnenburg et al. (2010) showed that many studied Bacteroides species (for 330 
example B. thetaiotaomicron and B. vulgatus) did not grow on inulin. (Sonnenburg et al., 331 
2010).  332 
 333 
Varied responses to inulin and levan were found for different group of Clostridium, including 334 
commensal (Eubacterium rectale- Clostridium coccoides groups, Clostridium cluster IX, 335 
Roseburia spp. and Faecalibacterium prausnitzii) and pathogenic species (Clostridium 336 
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histolyticum). Significant stimulation (p<0.05) of Eubacterium rectale- Clostridium 337 
coccoides groups was observed for both test substrates in all vessels, and populations of this 338 
group of bacteria were significantly higher in all three vessels in the models treated with 339 
levan than with inulin HP. Significant increase in population of Roseburia was observed in 340 
all vessels treated with both substrates. A different result has been reported by Ramirez-341 
Farias et al. (2008) that no significant increase was found in number of Roseburia after inulin 342 
supplementation as a mean of all volunteers. However, they also documented a strong 343 
increase upon inulin ingestion of two volunteers and suggested a possible variance between 344 
volunteers in which different strain/species of Roseburia were present (Ramirez-Farias et al., 345 
2008). This assumption was then supported by Sheridan et al. (2016), who found that all 346 
tested R. inulinivorans strains were capable of utilizing inulin, whereas R. intestinalis, R. 347 
hominis and R. faecis strains did not grow on inulin as the sole carbohydrate source (Sheridan 348 
et al., 2016). Clostridium cluster IX also showed a significant decrease (ranging from 0.34 to 349 
0.73 log cells/mL) in all vessels treated with both substrates. A similar finding has been 350 
reported by Van de Wiele et al. (2006), in which the numbers of clostridia decreased after 351 
intervention with inulin HP using SHIME model at a dose of 2.5 g/day. The population of 352 
Faecalibacterium prausnitzii, significantly decreased in the models with added inulin HP in 353 
all three vessels (0.57 log cells/mL decrease in V1, 0.44 log cells/mL decrease in V2 and 0.3 354 
log cells/mL decrease in V3), while the addition of levan-type fructan led to an increase in 355 
vessel 2 (0.25 log cells/mL), after a decrease in vessel 1 (0.61 log cells/mL), also suggesting a 356 
transit-dependent effect. In contrast to the present study, many researchers have documented 357 
stimulative effects of inulin on the population of F. prausnitzii (Lopez-Siles et al., 2017; 358 
Ramirez-Farias et al., 2008). Besiders, Kleessen et al. (2007) reported that no significant 359 
change was observed in F. prausnitzii counts in volunteers consumed snack bars containing 360 
inulin (7.7 g/d) after a 7-d run-in period. However, Moens and De Vuyst (2017) studied the 361 
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utilisation of inulin by F. prausnitzii in pure cultures and suggested that F. prausnitzii could 362 
degrade both FOS and inulin. Moreover, Moen et al. (2016) documented that a cross-feeding 363 
interactions between bifidobacteria and acetate-depending, butyrate-producing F. prausnitzii 364 
was observed and can be either a beneficial relationship or dominated by competition, 365 
depending on the inulin degradation capacities of the bifidobacterial strains involved. 366 
Therefore, decrease in number of F. prausnitzii seen in the present study could be possibly 367 
explained by the competition between F. prausnitzii and other dominating gut microbes. 368 
However, this will have to be confirmed in other intervention studies. In addition, no 369 
significant changes were observed for Clostridium histolyticum. This is in line with the 370 
results of Tuohy et al. (2002) and Harmsen et al. (2002), in which this groups of bacteria 371 
were unaffected by supplementation with inulin HP. 372 
 373 
For the Atopobium cluster, with addition of inulin HP, no significant increase was observed in 374 
the first two vessels, but there was a 0.31 log cells/mL increase in vessel 3, suggesting a 375 
stimulation effect in the distal colon. This cluster of bacteria is a dominant member of the 376 
faecal microbiota of healthy humans, which making up around 8 % of the microbiota 377 
(Thorasin et al., 2015). The result found in the present study is in good agreement with 378 
Costabile et al. (2010), who also reported a significant increase of Atopobium after 14 days 379 
supplementation with inulin. However, no significant difference was obtained with addition 380 
of levan-type fructan across all three vessels.  381 
 382 
Briefly, both inulin and levan contributed to beneficial shifts towards the gut microbial 383 
composition, indicated by significant increase in population of Bifidobacterium spp. Such 384 
bifidogenic effect is widely accepted as beneficial to the host health due to the carbohydrate- 385 
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fermenting pattern of bacteria strains belong to the genus Bifidobacterium (Meyer and Stasse-386 
Wolthuis, 2009). Also, a stronger bifidogenic effect of levan-type fructan has been observed.  387 
Various groups of commensal bacteria were enumerated and some of them showed different 388 
responses between the two types of fructans. The main differences were among the changes 389 
in the populations of the Bacteroides-Prevotella group, Atopobium cluster and F prausnitzii, 390 
due to their capacities of using different fructans in the complex gut ecosystem. In addition, 391 
no stimulation of pathogenic clostridia (Clostridium histolyticum) was observed for both 392 
substrates, indicating that no adverse effect on the host health was induced by inulin and 393 
levan supplementation in terms of their effects on Clostridium histolyticum.  394 
 395 
Compared with inulin, the effect of levan-type fructans on the human gut microbiota has 396 
hitherto only been studied using batch cultures. Marx et al. (2000) tested the abilities of 397 
various bacterial genera to ferment long chain levan and levan oligosaccharides in pure 398 
cultures, including several strains of Bifidobacterium and found that only levan 399 
oligosaccharides demonstrated an enrichment effect on the tested strains (B. adolescentis, B. 400 
breve, B. longum and B. pseudocatenulatum). In another study, the in vitro fermentation 401 
properties of a commercial levan from Sigma (originating from Erwinia herbicola) and two 402 
self-isolated levan-type exopolysaccharides (originating from Lactobacillus sanfranciscensis) 403 
were studied using human faeces as an inoculum (Bello et al., 2001). An enrichment of 404 
Bifidobacterium species was found with the levan type exopolysaccharides produced by 405 
Lactobacillus sanfranciscensis, but not for levan from Erwinia herbicola. Levan synthesized 406 
using levansucrase from Pseudomonas syringae was found to act as an easily degradable 407 
substrate for Bacteroides thetaiotaomicron when tested with pure culture (Adamberg et al., 408 
2014). Mardo et al. (2017) reported that the endo-levanase from B. thetaiotaomicron can 409 
degrade various β-2, 6-linked polyfructan levans. They also suggested that the long chain 410 
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levan molecules were degraded into FOS with a cell surface bound endo-levanase BT1760, 411 
and the FOS was then consumed by B. thetaiotaomicron and other gut bacteria, including 412 
health-promoting bifidobacteria and lactobacilli (Mardo et al., 2017). Such cross-feeding 413 
effect was previously documented by Rakoff-Nahoum et al. (2014), who reported that 414 
fructose and oligosaccharides liberated from levan metabolized by B. thetaiotaomicron could 415 
support the growth of Bacteroidales species without levan utilising ability. Crystal structure 416 
of the BT1760 supported this assumption once again (Ernits et al., 2019). Hamdy et al. 417 
(2018) investigated the prebiotic activity of Bacillus levan in rat feeding trails. They found 418 
that levans produced by two strains of Bacillus subtilis (HMNig-2 and MENO2) both have 419 
the ability of lowing coliform count and increasing lactobacillus count in gut especially when 420 
used together which the probiotic strain B. subtilis HMNig-2 and MENO2. More recently, 421 
both natural levan from Erwinia herbicola, and a low molecular weight (8 kDa), highly 422 
branched levan from Bacillus amyloliquefaciens JN4 were shown to exhibit antiadhesive 423 
activity against enterotoxigenic Escherichia coli, whereas such activity was not found with 424 
chicory inulin (Cai et al., 2019) The fermentation of levanheptaose on some components of 425 
the intestinal microbiota was studied by Kang et al (2000) using pure cultures. Growth of 426 
Bifidobacterium adolescentis, Lactobacillus acidophilus and Eubacterium limosum were 427 
stimulated, whereas numbers of Clostridium perfringens, E. coli and Staphylococcus aureus 428 
remain unchanged compared with control cultures.  Kang et al (2000) also studied the effect 429 
of levanheptaose on the gut microbiota of rats. The ingestion of levanheptaose resulted in a 1 430 
log cell/ mL increase in the faecal counts of endogenous bifidobacteria, without affecting 431 
Lactobacillus sp. The amount of butyrate as well as β-fructosidase activity were increased, 432 
whereas pH was reduced in rats fed levanheptaose diets as compared to those on the control 433 




The molecular weight of a fructan has an effect on the fermentation behaviour (Biedrzycka 436 
and Bielecka, 2004). The results of in vitro studies using pure cultures indicate the specificity 437 
for Bifidobacterium spp., with the exception of B. bifidum, when utilising short chain 438 
fructooligosaccharides and inulins of average DP over 9, but not highly polymerized inulins 439 
(average DP = 40). The results of subsequent in vivo studies on rats also suggested the 440 
selectivity of fructooligosaccharides and low DP inulins, for Bifidobacterium spp., while the 441 
effects of highly polymerized inulin were more diverse and related to the presence and ability 442 
of other bacteria to initiate degradation (Biedrzycka and Bielecka, 2004). On the other hand, 443 
degree of branching also has effects on the fermentation property of levan. Although this 444 
effect has not been fully understood, Yoon et al. (2004) found that anti-tumour activity of 445 
levan towards SNU-1 and HepG2 tumour cell lines decreased rapidly as the degree of 446 
branching reduced. Also，Benigar et al. (2014) found that levan from three different origins 447 
(i.e. Bacillus subtilis, Zymomonas mobilis, and Erwinia herbicola) differed in their structural 448 
and dynamic properties in aqueous solutions. Their Small-Angle X-ray Scattering result 449 
indicated that, in aqueous solution, Bacillus subtilis levan was the least entangled with the 450 
most flexible structure while Erwinia herbicola levan was the most entangled, reflected in 451 
higher solution turbidity at the same concentration (Beinigar et al., 2014). Factors affecting 452 
the particle-forming property were mainly MW and branching of levan molecules. 453 
Furthermore, as reported by Bello et al. (2001), a bifidogenic effect was not found with 454 
natural Erwinia herbicola levan compared with levan from other sources, we hypothesised 455 
that this particle-forming property could possibly limit the contact between digestion 456 
enzymes of gut bacteria and natural levan molecules and hence restrict their bioactivity. In 457 
the current study, after acid hydrolysis, turbidity of levan solution was reduced to a great 458 
extent and the hydrolysed levan (DP =137) showed enhanced prebiotic potential comparing 459 
with inulin HP as well as a gut persistence given by large molecular weight. 460 
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   463 
Fig. 2. Mean bacterial populations (log10 cell per mL) in each vessel of the three-stage continuous system (vessel 1, 2 and 3) at steady state 1 and steady state 464 
2. Standard deviation is shown in parentheses with n=3. *denoted a significant change in bacterial number in SS2 compared to SS1 at P < 0.05; ** denoted a 465 
significant change in bacterial number in SS2 compared to SS1 at P < 0.01. SS1: Steady state 1, fermentation without adding test substrate; SS2: steady state 2, after 466 
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3.3 Short chain fatty acid production 468 
Changes in SCFA concentrations are shown in Fig. 3. In the gut model system, SCFA 469 
accumulate across all three vessels, which is not physiological so only changes in vessel will 470 
be discussed here. Acetate, butyrate, and propionate were the three main SCFAs 471 
accumulating during fermentation. The concentration of acetate significantly (p<0.05) 472 
increased in all three vessels for both test substrates ranging from 14.16 mM to 30.37 mM, 473 
while both inulin HP and levan-type fructan led to a large increase in vessel 1 (30.37mM and 474 
29.74 mM, respectively), with no significant differences between them. This is consistent 475 
with the changes in number of Bifidobacterium spp., which is known as a lactate and acetate 476 
producer. Lactate was not detected in any vessel due to consumption by butyrate producing 477 
bacteria such as Clostridium cluster IV (e.g. Faecalibacterium prausnitzii group and 478 
Eubacterium rectale- Clostridium coccoides group) and XIVa (e.g. Roseburia spp.).  479 
Accordingly, the butyrate concentration also increased significantly after the intervention, 480 
both substrates giving rise to significant increases ranging from 26.03 mM to 65.41mM, in 481 
line with the increase in number of Clostridium cluster IV and XIVa. Enrichment in acetate 482 
and butyrate production has been reported by many inulin intervention studies (Alexander et 483 
al., 2018; Thøgersen et al.,2018; van der Beek et al., 2018). Moreover, similar result has been 484 
documented regarding levan-type fructan. Adamberg et al. (2018) found that administration 485 
of levan corrected the metabolic pattern of overweight children faecal consortium by 486 
increasing the production of butyrate and acetate. Besides, as the concentration of acetate and 487 
butyrate increased, the accumulation of propionate significantly decreased after addition of 488 
inulin HP while treatment with levan-type fructan did not affect the propionate concentration 489 
significantly. This is the main difference between SCFAs production induced by 490 
supplementation of two tested substrates and is consistent with the changes in number of 491 
Bacteroides – Prevotella, which is known as an acetate, lactate, and propionate producer.  492 
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Total organic acids also significantly increased in all vessels. There was no significant 493 
difference between the test substrates. 494 
  495 
Overall, a possible route of levan metabolism was proposed based on the experimental data 496 
of the present study and information from the literature. Levans are firstly degraded by 497 
Bifidobacterium, Bacteroides, and Lactobacillus to produce fructose, FOS and organic acids, 498 
especially lactate and acetate. The hydrolysis products and SCFAs are then utilized by 499 
butyrate-producing bacteria (such as Eubacterium, Faealibacterium and Roseburia) and other 500 




   502 
Fig. 3 Mean short chain fatty acid concentration (mM) in each vessel of the three-stage continuous system (vessel 1, 2 and 3) at steady state 1 and 503 
steady state 2, Standard deviation is shown in parentheses with n=3. *denoted a significant change in bacterial number in SS2 compared to SS1 at P < 0.05; ** denoted a 504 
significant change in bacterial number in SS2 compared to SS1 at P < 0.01. SS1: Steady state 1, fermentation without adding test substrate; SS2: steady state 2, after 505 
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4. Conclusion 507 
The in vitro fermentation of a hydrolysis product of levan (average DP =137), produced from 508 
Erwinia sp. 10119 was investigated in pH controlled three-stage compound continuous gut 509 
model systems compared with inulin HP (average DP = 40). Bifidobacterium and 510 
Eubacterium rectale - Clostridium coccoides groups significantly increased in all vessels 511 
including the 3rd vessel simulating the distal colon. The increases were significantly higher in 512 
the models treated with levan-type fructan (0.8 to1.24 log cell/mL) compared to the inulin HP 513 
models (0.62-0.7 log cell/mL), indicating a stronger bifidogenic effect of levan-type fructan 514 
and prolonged persistence in the colon due its higher DP. Both acetate and butyrate 515 
significantly increased in all the vessels of the system, although no significant difference was 516 
observed between them. The structural differences among levan from different 517 
microorganisms have not been determined in this study. However, it has been reported by 518 
various researchers that the molecular weight and degree of branching varies among levans 519 
from different producers, which most likely results in differences in their fermentation 520 
properties. Thus, it would be valuable to evaluate these relationships in well designed in vitro 521 
and in vivo studies with the aim to develop novel prebiotics based on these polymers.     522 
 523 
Acknowledgement 524 
This research did not receive any specific grant from funding agencies in the public, 525 







Abdel-Fattah, A. M., Gamal-Eldeen, A. M., Helmy, W. A., & Esawy, M. A. (2012). 531 
Antitumor and antioxidant activities of levan and its derivative from the isolate Bacillus 532 
subtilis NRC1aza. Carbohydrate polymers, 89, 314-322. 533 
Adamberg, K., Adamberg, S., Ernits, K., Larionova, A., Voor, T., Jaagura, M., … Alamäe, T. 534 
(2018). Composition and metabolism of fecal microbiota from normal and overweight 535 
children are differentially affected by melibiose, raffinose and raffinose-derived fructans. 536 
Anaerobe, 52, 100–110.  537 
Adamberg, K., Tomson, K., Talve, T., Pudova, K., Puurand, M., & Visnapuu, T. (2015).  538 
Levan enhances associated growth of Bacteroides, Escherichia, Streptococcus and 539 
Faecalibacterium in faecal microbiota. PLoS One. 10, 1-19. 540 
Adamberg, S., Tomson, K., Vija, H., Puurand, M., Kabanova, N., & Visnapuu, T. (2014). 541 
Degradation of Fructans and Production of Propionic Acid by Bacteroides 542 
thetaiotaomicron are Enhanced by the Shortage of Amino Acids. Frontiers in Nutrition, 1, 543 
1–10. 544 
Ahmed, W., & Rashid, S. (2017). Functional and therapeutic potential of inulin: A 545 
comprehensive review. Critical Reviews in Food Science and Nutrition, 59(1), 1–13. 546 
Almeida, A., Mitchell, A. L., Boland, M., Forster, S. C., Gloor, G. B., Tarkowska, 547 
A., …Finn, R. D., (2019). A new genomic blueprint of the human gut microbiota. Nature 548 
568, 499 –504. 549 
Alexander, C., Cross, T. W. L., Devendran, S., Neumer, F., Theis, S., Ridlon, J. M., … 550 
Swanson, K. S. (2018). Effects of prebiotic inulin-Type fructans on blood metabolite and 551 
hormone concentrations and faecal microbiota and metabolites in overweight dogs. Clay 552 
Minerals, 120, 711–720. 553 
Andriamihaja, M., Lan, A., Beaumont, M., Audebert, M., Wong, X., Yamada, K., … 554 
Blachier, F. (2015). The deleterious metabolic and genotoxic effects of the bacterial 555 
metabolite p-cresol on colonic epithelial cells. Free Radical Biology and Medicine, 85, 556 
219-227. 557 
Ávila-Fernández, Á., Cuevas-Juárez, E., Rodríguez-Alegría, M. E., Olvera, C., & López-558 
Munguía, A. (2016). Functional characterization of a novel β-fructofuranosidase from 559 
Bifidobacterium longum subsp. infantis ATCC 15697 on structurally diverse fructans. 560 
Journal of Applied Microbiology, 121, 263-276.  561 
Bello, D. F., Walter, J., Hertel, C., & Hammes, W. P. (2001). In vitro study of prebiotic 562 
properties of levan-type exopolysaccharides from lactobacilli and non-digestible 563 
carbohydrates using denaturing gradient gel electrophoresis. Systematic and Applied 564 
Microbiology, 24, 232-237. 565 
Benigar, E., Dogsa, I., Stopar, D., Jamnik, A., Cigić, I. K., & Tomšič, M. (2014). Structure 566 
and dynamics of a polysaccharide matrix: Aqueous solutions of bacterial levan. Langmuir, 567 
30(14), 4172–4182. 568 
Biedrzycka, E., & Bielecka, M. (2004). Prebiotic effectiveness of fructans of different degrees 569 
of polymerization. Trends in Food Science & Technology, 15, 170–175.  570 
30 
 
Cai, G., Liu, Y., Li, X., & Lu, J. (2019).  New Levan-Type Exopolysaccharide from Bacillus 571 
amyloliquefaciens as an Antiadhesive Agent against Enterotoxigenic Escherichia coli. 572 
Journal of Agricultural and Food Chemistry, 67(28), 8029–8034. 573 
Calazans, G. M., Lima, R. C., de França, F. P., & Lopes, C. E. (2000). Molecular weight and 574 
antitumour activity of Zymomonas mobilis levans. International Journal of Biological 575 
Macromolecules, 27, 245-247. 576 
Charalampopoulos, D., & Rastall, R. A. (2012). Prebiotics in foods. Current opinion in 577 
biotechnology, 23, 187-191. 578 
Corradini, C., Bianchi, F., Matteuzzi, D., Amoretti, A., Rossi, M., & Zanoni, S. (2004). High-579 
performance anion-exchange chromatography coupled with pulsed amperometric detection 580 
and capillary zone electrophoresis with indirect ultra violet detection as powerful tools to 581 
evaluate prebiotic properties of fructooligosaccharides and inulin. Journal of 582 
Chromatography A, 1054, 165-173. 583 
Costabile, A., Kolida, S., Klinder, A., Gietl, E., Bäuerlein, M., Frohberg, C., & Gibson, G. R. 584 
(2010). A double-blind, placebo-controlled, cross-over study to establish the bifidogenic 585 
effect of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) in 586 
healthy human subjects. British journal of nutrition, 104, 1007-1017. 587 
Dahech, I., Belghith, K. S., Hamden, K., Feki, A., Belghith, H., & Mejdoub, H. (2011). 588 
Antidiabetic activity of levan polysaccharide in alloxan-induced diabetic 589 
rats. International journal of biological macromolecules, 49, 742-746. 590 
Dahech, I., Harrabi, B., Hamden, K., Feki, A., Mejdoub, H., Belghith, H., & Belghith, K. S. 591 
(2013). Antioxidant effect of nondigestible levan and its impact on cardiovascular disease 592 
and atherosclerosis. International journal of biological macromolecules, 58, 281-286. 593 
Daims, H., Brühl, A., Amann, R., Schleifer, K. H., & Wagner, M. (1999). The Domain-specific 594 
Probe EUB338 is Insufficient for the Detection of all Bacteria Development and Evaluation 595 
of a more Comprehensive Probe Set. Systematic and applied microbiology, 22, 434-444. 596 
De Preter, V., Vanhoutte, T., Huys, G., Swings, J., De Vuyst, L., Rutgeerts, P., & Verbeke, 597 
K. (2007). Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and 598 
oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. 599 
American Journal of Physiology: Gastrointestinal and Liver Physiology, 292, 358-368. 600 
Diplock, A. T., Aggett, P. J., Ashwell, M., Bornet, F., Fern, E. B., & Roberfroid, M. B. 601 
(1999). Scientific concepts of functional foods in Europe: consensus document. British 602 
Journal of Nutrition, 81, S1-S27. 603 
Ernits, K., Eek, P., Lukk, T., Visnapuu, T., & Alamäe, T. (2019). First crystal structure of an 604 
endo-levanase - the BT1760 from a human gut commensal Bacteroides thetaiotaomicron. 605 
Scientific Reports, 9(1), 8443. 606 
Esawy, M. A., Amer, H., Gamal-Eldeen, A. M., El Enshasy, H. A., Helmy, W. A., Abo-Zeid, 607 
M. A., & Awad, G. E. (2013). Scaling up, characterization of levan and its inhibitory role 608 
in carcinogenesis initiation stage. Carbohydrate polymers, 95, 578-587. 609 
31 
 
Franks, A. H., Harmsen, H. J., Raangs, G. C., Jansen, G. J., Schut, F., & Welling, G. W. (1998). 610 
Variations of bacterial populations in human feces measured by fluorescent in situ 611 
hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Applied and 612 
Environmental Microbiology, 64, 3336-3345. 613 
Gibson, G.R. 2004. Fibre and effects on probiotics (the prebiotic concept). Clinical Nutrition 614 
Supplements, 1, 25–31.  615 
Gibson, G. R., Probert, H. M., Van Loo, J., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary 616 
modulation of the human colonic microbiota: updating the concept of prebiotics. Nutrition 617 
Research Reviews, 17, 259-275. 618 
Gibson, G. R., Scott, K. P., Rastall, R. A., Tuohy, K. M., Hotchkiss, A., Dubert-Ferrandon, A., 619 
Gareau, M., Murphy, E. F., Saulnier, D., Loh, G., Macfarlane, S., Delzenne, N., Ringel, Y., 620 
Kozianowski, G., Dickmann, R., Lenoir-Wijnkook, I., Walker, C., & Buddington, R. (2010). 621 
Dietary prebiotics: current status and new definition. IFIS Functional Foods Bulletin, 7, 1-622 
19. 623 
Gibson, G. R., & Wang, X. (1994). Enrichment of bifidobacteria from human gut contents by 624 
oligofructose using continuous culture. FEMS Microbiology Letters, 118, 121-127. 625 
Hamdy, A. A., Elattal, N. A., Amin, M. A., Ali, A. E., Mansour, N. M., Awad, G. E., Farrag, 626 
A. R. H., & Esawy, M. A. (2018). In vivo assessment of possible probiotic properties 627 
of Bacillus subtilis and prebiotic properties of levan. Biocatalysis and Agricultural 628 
Biotechnology, 13, 190–197. 629 
Harmsen, H. J., Elfferich, P., Schut, F., & Welling, G. W. (1999). A 16S rRNA-targeted probe 630 
for detection of lactobacilli and enterococci in faecal samples by fluorescent in situ 631 
hybridization. Microbial Ecology in Health and Disease, 11, 3-12. 632 
Harmsen, H. J., Raangs, G. C., Franks, A. H., Wildeboer-Veloo, A. C., & Welling, G. W. 633 
(2002). The effect of the prebiotic inulin and the probiotic Bifidobacterium longum on the 634 
faecal microflora of healthy volunteers measured by FISH and DGGE. Microbial Ecology 635 
in Health and Disease, 14, 212-220. 636 
Hongpattarakere, T., Cherntong, N., Wichienchot, S., Kolida, S., & Rastall, R. A. (2012). In 637 
vitro prebiotic evaluation of exopolysaccharides produced by marine isolated lactic acid 638 
bacteria. Carbohydrate Polymers, 87, 846-852. 639 
Hughes, R., Kurth, M. J., McGilligan, V., McGlynn, H., & Rowland, I. (2008). Effect of 640 
colonic bacterial metabolites on Caco-2 cell paracellular permeability in vitro. Nutrition 641 
and Cancer, 60, 259–66. 642 
Ijssennagger, N., van der Meer, R., & van Mil, S. W. C. (2016). Sulfide as a Mucus Barrier-643 
Breaker in Inflammatory Bowel Disease? Trends in Molecular Medicine, 22(3), 190–199. 644 
Kang, S. A., Jang, K. H., Seo, J. W., Kim, K. H., Kim, Y. H., Rairakhwada, D., & Rhee, S. 645 
(2009). Levan: applications and perspectives. In: Rehm, B. H. A. (Eds.), Microbial 646 
production of biopolymers and polymer precursors (pp. 145-161). Norfolk: Caister 647 
Academic Press. 648 
32 
 
Kang, S. K., Park, S. J., Lee, J. D., & Lee, T. H. (2000). Physiological effects of 649 
levanoligosaccharide on growth of intestinal microflora. Journal of the Korean Society of 650 
Food Science and Nutrition, 29, 35-40 651 
Keith, J., Wiley, B., Ball, D., Arcidiacono, S., Zorfass, D., Mayer, J., & Kaplan, D. (1991). 652 
Continuous culture system for production of biopolymer levan using Erwinia herbicola. 653 
Biotechnology and Bioengineering, 38(5), 557–560. 654 
Kleessen, B., Schwarz, S., Boehm, A., Fuhrmann, H., Richter, A., Henle, T., & Krueger, M. 655 
(2007). Jerusalem artichoke and chicory inulin in bakery products affect faecal microbiota 656 
of healthy volunteers. British Journal of Nutrition, 98(3), 540–549. 657 
Koenen, M. E., Rubio, J. M. C., Mueller, M. & Venema, K. (2016). The effect of agave 658 
fructan products on the activity and composition of the microbiota determined in a 659 
dynamic in vitro model of the human proximal large intestine. Journal of Functional 660 
Foods, 22, 201–210. 661 
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber 662 
to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 663 
1332–1345. 664 
Laparra, J. M., & Sanz, Y. (2010). Interactions of gut microbiota with functional food 665 
components and nutraceuticals. Pharmacological Research, 61, 219-225. 666 
Li, Y., & Triccas, J. A., & Ferenci, T. (1997).  A novel levansucrase-levanase gene cluster in 667 
Bacillus stearothermophilus ATCC12980.  Biochimica et Biophysica Acta (BBA) - Gene 668 
Structure and Expression, 1353, 203–208. 669 
Lopez-Siles, M., Duncan, S. H., Garcia-Gil, L. J., & Martinez-Medina, M. (2017). 670 
Faecalibacterium prausnitzii: From microbiology to diagnostics and prognostics. ISME 671 
Journal, 11(4), 841–852. 672 
Macfarlane, G. T., Macfarlane, S., & Gibson, G. R. (1998). Validation of a three-stage 673 
compound continuous culture system for investigating the effect of retention time on the 674 
ecology and metabolism of bacteria in the human colon. Microbial Ecology, 35, 180-187. 675 
Manz, W., Amann, R., Ludwig, W., Vancanneyt, M., & Schleifer, K. H. (1996). Application 676 
of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of 677 
the phylum Cytophaga-Flavobacter-Bacteroides in the natural environment. Microbiology, 678 
142, 1097-1106 679 
Mardo, K., Visnapuu, T., Vijaet, H., Aasamets, A., Viigand, K., & Alama, T. (2017). A highly 680 
active endo-levanase BT1760 of a dominant mammalian gut commensal Bacteroides 681 
thetaiotaomicron cleaves not only various bacterial levans, but also levan of timothy grass, 682 
PLoS ONE, 12, 1–26.  683 
Martel, C. M., Warrilow, G. S., Jackson, C. J., Mullins, J. G. L., Togawa, R. C., & Parker, J. 684 
E. (2010). Expression, purification and use of the soluble domain of Lactobacillus paracasei 685 
β-fructosidase to optimise production of bioethanol from grass fructans. Bioresource 686 
Technology, 101, 4395–4402. 687 
33 
 
Marx, S. P., Winkler, S., & Hartmeier, W. (2000). Metabolization of beta-(2, 6)-linked 688 
fructose-oligosaccharides by different bifidobacteria. FEMS microbiology letters, 182, 163–689 
169.  690 
McBurney, M. I., Van Soest, P. J., & Jeraci, J. L. (1987). Colonic carcinogenesis: the 691 
microbial feast or famine mechanism. Nutrition and Cancer, 10, 23-28.  692 
Meyer, D., & Stasse-Wolthuis, M. (2009). The bifidogenic effect of inulin and oligofructose 693 
and its consequences for gut health. European Journal of Clinical Nutrition, 63(11), 1277–694 
1289. 695 
Moens, F., & de Vuyst, L. (2017). Inulin-type fructan degradation capacity of clostridium 696 
cluster IV and XlVa butyrate- producing colon bacteria and their associated metabolic 697 
outcomes. Beneficial Microbes, 8(3), 473–490. 698 
Moens, F, Weckx, S., & De Vuyst, L. (2016). Bifidobacterial inulin-type fructan degradation 699 
capacity determines cross-feeding interactions between bifidobacteria and 700 
Faecalibacterium prausnitzii. International Journal of Food Microbiology, 231, 76–85. 701 
Oliphant, K., & Allen-Vercoe, E. (2019). Macronutrient metabolism by the human gut 702 
microbiome: major fermentation by-products and their impact on host health. Microbiome, 703 
7(91), 1-15. 704 
Öner, E.T., Hernández, L., & Joan C. (2016). Review of Levan polysaccharide: From a 705 
century of past experiences to future prospects. Biotechnology Advances, 34, 827–844. 706 
Ortiz-Soto, M. E., Porras-Domínguez, J., Seibel, J., & López-Munguía, A. (2019). A close 707 
look at the structural features and reaction conditions that modulate the synthesis of low 708 
and high molecular weight fructans by levansucrases. Carbohydrate Polymers. 219, 130-709 
142. 710 
Patterson, J. K., Yasuda, K., Welch, R. M., Miller, D. D., & Lei, X. G. (2010). Supplemental 711 
dietary inulin of variable chain lengths alters intestinal bacterial populations in young 712 
pigs. The Journal of nutrition, 140, 2158-2161. 713 
Porras-Dominguez, J. R., Avila-Fernandez, A., Rodriguez-Alegria, M. E., Miranda-Molina, 714 
A., Escalante, A., & Gonzlez-Cervantes, R. (2014). Levan-type FOS production using a 715 
Bacillus licheniformis endolevanase. Process Biochemistry, 49, 783–790. 716 
Rakoff-Nahoum, S., Coyne, M. J., & Comstock, L. E. (2014). An ecological network of 717 
polysaccharide utilization among human intestinal symbionts. Current Biology, 24(1), 40–718 
49. 719 
Ramirez-Farias, C., Slezak, K., Fuller, Z., Duncan, A., Holtrop, G., & Louis, P. (2008). Effect 720 
of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and 721 
Faecalibacterium prausnitzii. British Journal of Nutrition, 101(04), 533. 722 
Rastall, R. A., & Maitin, V. (2002). Prebiotics and synbiotics: towards the next generation. 723 
Current opinion in biotechnology, 13, 490-496. 724 
Roberfroid, M. B. (2007). Inulin-type fructans: functional food ingredients. The journal of 725 
nutrition, 137, 2493-2502. 726 
Roberfroid, M. B., Van Loo, F., & Gibson, G. R. (1998). The bifidogenic nature of chicory 727 
inulin and oligofructose. Journal of Nutrition, 128, 11-19. 728 
34 
 
Rumessen, J. J., Bode, S., Hamberg, O., & Gudmand-Hoyer, E. (1990). Fructans of 729 
Jerusalem artichokes: intestinal transport, absorption, fermentation, and influence on blood 730 
glucose, insulin, and C-peptide responses in healthy subjects. The American Journal of 731 
Clinical Nutrition, 52, 675-681. 732 
Sarbini, S. R., Kolida, S., Naeye, T., Einerhand, A., Brison, Y., Remaud-Simeon, M., Monsan, 733 
P., Gisbson, G. R., & Rastall, R. A. (2011). In vitro fermentation of linear and alpha-1, 2-734 
branched dextrans by the human faecal microbiota. Applied Environental Microbiology, 77, 735 
5307-5315. 736 
Shoaib, M., Shehzad, A., Omar, M., Rakha, A., Raza, H., Sharif, H. R., … Niazi, S. 737 
(2016). Inulin: Properties, health benefits and food applications. Carbohydrate Polymers, 738 
147, 444–454 739 
Sghir, A, Chow, J. M., & Mackie, R. I. (1998). Continuous culture selection of bifidobacteria 740 
and lactobacilli from human faecal samples using fructooligosaccharide as selective 741 
substrate. Journal of Applied Microbiology, 85, 769–777. 742 
Sonnenburg, E. D., Zheng, H., Joglekar, P., Higginbottom, S. K., Firbank, S. J., & Bolam, D. 743 
N. (2010). Specificity of polysaccharide use in intestinal bacteroides species determines 744 
diet-induced microbiota alterations. Cell, 141, 1241–1252. 745 
Srikanth, R., Reddy, C. H. S. S. S., Siddartha, G., Ramaiah, M. J., & Uppuluri, K. B. (2015). 746 
Review on production, characterization and applications of microbial levan. Carbohydrate 747 
Polymers, 120, 102–114. 748 
Thøgersen, R., Castro-Mejía, J. L., Sundekilde, U. K., Hansen, L. H., Hansen, A. K., Nielsen, 749 
D. S., & Bertram, H. C. (2018). Ingestion of an Inulin-Enriched Pork Sausage Product 750 
Positively Modulates the Gut Microbiome and Metabolome of Healthy Rats. Molecular 751 
Nutrition & Food Research, 13, e1800608. 752 
Thorasin, T., Hoyles, L., & McCartney, A. L. (2015). Dynamics and diversity of the 753 
‘Atopobium cluster’ in the human faecal microbiota, and phenotypic characterization of 754 
‘Atopobium cluster’ isolates. Microbiology (United Kingdom), 161(3), 565–579. 755 
Tuohy, K. M., Finlay, R. K., Wynne, A. G., & Gibson, G. R. (2001). A Human Volunteer Study 756 
on the Prebiotic Effects of HP-Inulin—Faecal Bacteria Enumerated Using Fluorescent In 757 
situ Hybridisation (FISH). Anaerobe, 7, 113-118. 758 
Van der Beek, C. M., Canfora, E. E., Kip, A. M., Gorissen, S. H. M., Olde Damink, S. W. 759 
M., van Eijk, H. M., … Lenaerts, K. (2018). The prebiotic inulin improves substrate 760 
metabolism and promotes short-chain fatty acid production in overweight to obese men. 761 
Metabolism, 87, 25–35. 762 
Van de Wiele, T., Boon, N., Possemiers, S., Jacobs, H., & Verstraete, W. (2004) Prebiotic 763 
effects of chicory inulin in the simulator of the human intestinal microbial ecosystem. 764 
FEMS Microbiology Ecology, 51, 143–153. 765 
35 
 
Van de Wiele, T., Boon, N., Possemiers, S., Jacobs, H., & Verstraete, W. (2007). Inulin‐type 766 
fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. 767 
Journal of applied microbiology, 102, 452-460. 768 
Walker, A. W., Duncan, S. H., Leitch, E. C. M., Child, M. W., & Flint, H. J. (2005). pH and 769 
peptide supply can radically alter bacterial populations and short-chain fatty acid ratios 770 
within microbial communities from the human colon. Applied and environmental 771 
microbiology, 71, 3692-3700. 772 
Yong, J. G., Lee, J. H., & Hutkins, R. W. (2007). Functional analysis of the 773 
fructooligosaccharide utilization operon in Lactobacillus paracasei 1195.  Applied and 774 
environmental Microbiology, 73, 5716–5724. 775 
Yoon, E. J., Yoo, S. H., Cha, J., & Gyu Lee, H. (2004). Effect of levan’s branching structure 776 
on antitumor activity. International journal of biological macromolecules, 34, 191-194. 777 
